FUJIFILM Holdings Corporation has 283 consolidated subsidiaries worldwide – with 77,739 employees – who all contribute to the output of this dynamic organization, working tirelessly to improve the quality of our collective lives.
GLOBAL REVENUE (as of Mar, 2018)
GLOBAL HEALTHCARE REVENUE
MILESTONE AND ACHIEVEMENTS
With its wide range of technologies and expansive vision, Fujifilm leverages the products, services, and hard-earned expertise that is rooted in the development of photographic products to enhance the quality of life of people worldwide.
FOUNDATION OF THE COMPANY
The company (Fuji Photo Film Co., Ltd.) was established in1934 with the aim of being the first Japanese producer of photographic films
First steps in Healthcare with X-ray film
Our first steps in the development of X-ray film in 1936, and later advances in imaging film and archiving film set the course for a long line of breakthrough technologies.
First steps in IVD with Dri-Chem (Dry Clinical Chemistry)
Our first steps in the development of Dry Clinical Chemistry analyzer in 1984, and later advances in imaging film and archiving film set the course for a long line of breakthrough technologies.
Expanding Dri-Chem Series (Dry Clinical Chemistry)
Following our first Dry Clinical Chemistry analyzer; Dri-Chem 1000, we have been evolving the dry chemistry technology and released multiple Dri-Chem analyzers.
Launching the first Immunological POC system
Our first steps in the development of POC Immunological test in 2011. Immuno AG1 for the early detection of Influenza Virus, and Immuno AU10V(*) as the first in-house POC analyzer for TSH measurement for Veterinarians. (*) Immuno AU10V: for Veterinary use only.
Next generation Dri-Chem: NX700, NX500, NX10
While retaining the characteristics of Dri-Chem series, NX series provides one rank higher usability. NX series can be operated intuitively so that all types of healthcare providers can use it for their patient care. Click images to see details.
Acquisition of WAKO PURECHEMICAL
In 2017, Fujifilm acquired a Japanese leading reagent manufacturer Wako Pure Chemical Industries, Ltd. to generate the substantial synergies in the area of regenerative medicine, in-vitro diagnosis (IVD) and pharmaceutical CDMO. The acquisition of Wako will be a key milestone for Fujifilm's future business growth.
Next Generation RAPID DIAGNOSTICS SYSTEM: IMMUNO AG2
With IMMUNO AG2 we have realized the easier and intuitive operation while retaining the unique features of IMMUNO AG1 which had been selected by more than 14,000 healthcare provides WW.
Click images to see details.
First steps in FECAL IMMUNOCHEMICAL TEST (FIT)
Our first steps in fighting against Colorectal cancer which is #2 common cause of cancer related death in Europe (#2 common cancer in Women after Breast Cancer, and #3 most common cancer in Men after lung and prostate Cancer). Click images to see details.
And the future...
Our commitment: continue to invest for IVD
As one of Fujifilm's strategic fields, our commitment is to continue to innovate and invest in In-Vitro Diagnostics field. Fujifilm is Never Stop to evolve ourselves to contribute to the people's quality of life.
FUJIFILM IVD STORY
Our challenge started in 1984
We had evolved the technology which we had been cultivating in “Photo field” to develop our unique “Dry Clinical Chemistry Solution”
Our Commitment is to continue to invest in In-Vitro Diagnostics (IVD) field to contribute to the quality of life.
Check all News, Videos and Brochure
Interested? Contact us for more information.